Abstract:<p>Melanoma is the deadliest type of cancer that affects the largest organ of our body, the skin. In recent years, there is an increase in the incidence and aggressiveness of melanomas. The number of treatment options has grown considerably in the past few years, leading to significant improvements in both overall and progression-free survival. One of the attractive candidates in this wave of treatment options is a cell cycle controller: cyclin-dependent kinases (CDK) 4/6 inhibitors. CDK4/6, a class of serine/threonine kinases expressed in most cell types, controls the first gap phase (G1 to S) of the cell cycle, indicating its vital importance in both normal cellular processes as well as tumorigenesis. Up to 90% of melanoma patients have genomic mutations affecting various parts of CDK4/6 pathway. Noticeably, with the help of next-generation sequencing technology, mutations with high frequency in the CDK4 pathway were also identified in relatively rare subtypes of melanoma including acral melanoma and mucosal melanoma. Therefore, CDK4/6 inhibitors have emerged as powerful and promising anticancer therapies, especially in combination treatment with immunotherapies or other targeted therapies. In this review, we will provide an overview of current scientific knowledge regarding the oncogenic properties of CDK4/6 in melanomas, we mainly discuss the latest genomic and preclinical findings of CDK4 signaling in melanoma, the progress of CDK4 inhibition as combined with other therapies for overcoming resistance and summarize recent advances from clinical trials as well as ongoing studies which gives us a better scope into the effectiveness of CDK4/6 therapy in treating malignant melanomas.</p>

Research advances in the mechanism and role of CDK6 in tumorigenesis

Targeting CDK7 in oncology: The avenue forward.

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

Immunomodulatory Effects of CDK4/6 Inhibitors

Increased Cyclin-Dependent Kinase 6 Expression in Bladder Cancer

The role of CDK6 in cancer

CDK4 and CDK6 kinases: From basic science to cancer therapy

Potential Target of CDK6 Signaling Pathway for Cancer Treatment

CDK7 in Breast Cancer: Mechanisms of Action and Therapeutic Potential.

Recent Progress in CDK4/6 Inhibitors and PROTACs

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment.

Unveiling the impact of CDK8 on tumor progression: mechanisms and therapeutic strategies

Research Advances in Anticancer Cyclin-dependent-kinase Inhibitors

The Role of Targeting CDK4/6 in Cancer Immunotherapy

Getting under the skin: The role of CDK4/6 in melanomas

Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives

A review on the role of cyclin dependent kinases in cancers

The Research Progress of the Mechanism of CHK2 in Tumor

Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment

Targeting cyclin-dependent kinase 9 in cancer therapy